These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30793488)

  • 1. Establishment and molecular characterization of decitabine-resistant K562 cells.
    Wen XM; Zhang TJ; Ma JC; Zhou JD; Xu ZJ; Zhu XW; Yuan Q; Ji RB; Chen Q; Deng ZQ; Lin J; Qian J
    J Cell Mol Med; 2019 May; 23(5):3317-3324. PubMed ID: 30793488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer of miR-4755-5p through extracellular vesicles and particles induces decitabine resistance in recipient cells by targeting CDKN2B.
    Lei L; Wang Y; Liu R; Feng J; Tang J; Gou J; Guan F; Li X
    Mol Carcinog; 2023 Jun; 62(6):743-753. PubMed ID: 36825759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression.
    Lin J; Ma JC; Yang J; Yin JY; Chen XX; Guo H; Wen XM; Zhang TJ; Qian W; Qian J; Deng ZQ
    Oncogene; 2018 May; 37(18):2432-2443. PubMed ID: 29449695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
    Ando T; Nishimura M; Oka Y
    Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
    Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells.
    Ma J; Wen X; Xu Z; Xia P; Jin Y; Lin J; Qian J
    Cell Cycle; 2023 May; 22(10):1215-1231. PubMed ID: 37032592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.
    Tang LJ; Sun GK; Zhang TJ; Wu DH; Zhou JD; Ma BB; Xu ZJ; Wen XM; Chen Q; Yao DM; Qian J; Ma JC; Lin J
    Cancer Cell Int; 2019; 19():177. PubMed ID: 31333331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.
    Li L; Liu W; Sun Q; Zhu H; Hong M; Qian S
    Oxid Med Cell Longev; 2021; 2021():8877460. PubMed ID: 33532040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-103 confers the resistance to long-treatment of adriamycin to human leukemia cells by regulation of COP1.
    Wan L; Tian Y; Zhang R; Peng Z; Sun J; Zhang W
    J Cell Biochem; 2018 May; 119(5):3843-3852. PubMed ID: 29058777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
    Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
    Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
    Valdez BC; Li Y; Murray D; Corn P; Champlin RE; Andersson BS
    Leuk Res; 2010 Mar; 34(3):364-72. PubMed ID: 19732952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
    Huang L; Liu Z; Jiang H; Li L; Fu R
    J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
    Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
    Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
    Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR-155.
    Yu Y; Kou D; Liu B; Huang Y; Li S; Qi Y; Guo Y; Huang T; Qi X; Jia L
    Int J Lab Hematol; 2020 Aug; 42(4):464-472. PubMed ID: 32359033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of decitabine on proliferation and apoptosis of NB4 and K562 cells].
    Han XA; Zeng HL; Han YP; Sun EW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):356-60. PubMed ID: 23628032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
    Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
    Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.